Departments of Medicine, ontreal Heart Institute, University of Montreal, Canada (N.B., J.L.R.).
M. Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC. (S.R.S.).
Circ Heart Fail. 2018 Nov;11(11):e005531. doi: 10.1161/CIRCHEARTFAILURE.118.005531.
The STICH trial (Surgical Treatment for Ischemic Heart Failure) demonstrated a survival benefit of coronary artery bypass grafting in patients with ischemic cardiomyopathy and left ventricular dysfunction. The Society of Thoracic Surgeons (STS) risk score and the EuroSCORE-2 (ES2) are used for risk assessment in cardiac surgery, with little information available about their accuracy in patients with left ventricular dysfunction. We assessed the ability of the STS score and ES2 to evaluate 30-day postoperative mortality risk in STICH and a contemporary cohort (CC) of patients with a left ventricle ejection fraction ≤35% undergoing coronary artery bypass grafting outside of a trial setting.
The STS and ES2 scores were calculated for 814 STICH patients and 1246 consecutive patients in a CC. There were marked variations in 30-day postoperative mortality risk from 1 patient to another. The STS scores consistently calculated lower risk scores than ES2 (1.5 versus 2.9 for the CC and 0.9 versus 2.4 for the STICH cohort), and underestimated postoperative mortality risk. The STS and ES2 scores had moderately good C statistics: CC (0.727, 95% CI: 0.650-0.803 for STS, and 0.707, 95% CI: 0.620-0.795 for ES2); STICH (0.744, 95% CI: 0.677-0.812, for STS and 0.736, 95% CI: 0.665-0.808 for ES2). Despite the CC patients having higher STS and ES2 scores than STICH patients, mortality (3.5%) was lower than that of STICH (4.8%), suggesting a possible decrease in postoperative mortality over the past decade.
The 30-day postoperative mortality risk of coronary artery bypass grafting in patients with left ventricular dysfunction varies markedly. Both the STS and ES2 score are effective in evaluating risk, although the STS score tend to underestimate risk.
URL: https://www.clinicaltrials.gov. Unique identifier: NCT00023595.
STICH 试验(缺血性心力衰竭的冠状动脉旁路移植术)表明,在患有缺血性心肌病和左心室功能障碍的患者中,冠状动脉旁路移植术具有生存获益。胸外科医生协会(STS)风险评分和欧洲心脏手术风险评分-2(ES2)用于心脏手术的风险评估,但关于它们在左心室功能障碍患者中的准确性的信息很少。我们评估了 STS 评分和 ES2 在 STICH 试验和一个当代队列(CC)中的患者中的 30 天术后死亡率风险评估中的能力,这些患者的左心室射血分数≤35%,并在试验环境之外接受冠状动脉旁路移植术。
计算了 814 名 STICH 患者和 1246 名 CC 连续患者的 STS 和 ES2 评分。患者之间的 30 天术后死亡率风险存在明显差异。STS 评分始终计算出低于 ES2 的风险评分(CC 为 1.5 与 2.9,STICH 队列为 0.9 与 2.4),并且低估了术后死亡率风险。STS 和 ES2 评分具有中等良好的 C 统计量:CC(STS 为 0.727,95%CI:0.650-0.803,ES2 为 0.707,95%CI:0.620-0.795);STICH(STS 为 0.744,95%CI:0.677-0.812,ES2 为 0.736,95%CI:0.665-0.808)。尽管 CC 患者的 STS 和 ES2 评分高于 STICH 患者,但死亡率(3.5%)低于 STICH(4.8%),这表明在过去十年中,术后死亡率可能有所下降。
左心室功能障碍患者冠状动脉旁路移植术的 30 天术后死亡率风险差异很大。STS 和 ES2 评分都能有效地评估风险,尽管 STS 评分往往低估了风险。